DUBLIN--(BUSINESS WIRE)--The "Escherichia coli Infections - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Escherichia coli Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4, 1, 37 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 14 molecules, respectively.
Key Topics Covered
- Introduction
- Escherichia coli Infections - Overview
- Escherichia coli Infections - Therapeutics Development
- Escherichia coli Infections - Therapeutics Assessment
- Escherichia coli Infections - Companies Involved in Therapeutics Development
- Escherichia coli Infections - Drug Profiles
- Escherichia coli Infections - Dormant Projects
- Escherichia coli Infections - Discontinued Products
- Escherichia coli Infections - Product Development Milestones
- Appendix
Companies Mentioned
- ABAC Therapeutics SA
- Adenium Biotech ApS
- AstraZeneca Plc
- Atterx Biotherapeutics Inc
- ContraFect Corp
- Daiichi Sankyo Co Ltd
- Debiopharm International SA
- Emergent BioSolutions Inc
- F. Hoffmann-La Roche Ltd
- Hsiri Therapeutics LLC
- Immuron Ltd
- Innovation Pharmaceuticals Inc
- Johnson & Johnson
- Kyorin Pharmaceutical Co Ltd
- Meiji Seika Pharma Co Ltd
- Melinta Therapeutics Inc
- Merck & Co Inc
- Microbiotix Inc
- Nabriva Therapeutics plc
- Navigen Inc
- Northern Antibiotics Oy
- Nosopharm SAS
- Novabiotics Ltd
- Oxford Drug Design Ltd
- Paratek Pharmaceuticals Inc
- Phico Therapeutics Ltd
- Protein Potential LLC
- PTC Therapeutics Inc
- Recce Ltd
- Sealife PHARMA GMBH
- Syntiron LLC
- TCM Biotech International Corp
- Tetraphase Pharmaceuticals Inc
- Venus Medicine Research Center
For more information about this report visit https://www.researchandmarkets.com/research/ktrs6q/escherichia_coli?w=4
